<p>麦克森公司（NYSE:MCK - 获取免费报告）获得了覆盖该公司的十七家券商的平均推荐评级为 “适度买入”，Marketbeat 报道。三位投资分析师对该股票给予了持有评级，十四位分析师给予了买入评级。在过去一年中更新了对该股票覆盖的券商中，平均 12 个月目标价为 970.7333 美元。</p>
<ul>
<li>3 只可能下一个宣布股票拆分的股票</li>
</ul>
<p>一些研究公司最近对 MCK 发布了报告。摩根大通将麦克森的目标价从 1,107.00 美元下调至 1,015.00 美元，并在周五的研究报告中对该公司给予了 “增持” 评级。Leerink Partners 在 3 月 5 日的研究报告中重申了 “跑赢大盘” 评级，并对麦克森的股票设定了 1,085.00 美元的目标价。Evercore 在 3 月 5 日的研究报告中重申了对麦克森股票的 “跑赢大盘” 评级。Raymond James Financial 在 3 月 5 日的研究报告中设定了麦克森股票的 970.00 美元目标价。最后，德意志银行在周五的研究报告中重申了 “买入” 评级，并对麦克森股票设定了 875.00 美元的目标价。</p>
<p><strong>阅读我们关于 MCK 的最新研究报告</strong></p>
<h2>关于麦克森的热门头条</h2>
<ul>
<li>3 只悄然提高分红的股息增长股票</li>
</ul>
<p>以下是本周影响麦克森的主要新闻：</p>
<ul>
<li>积极情绪：麦克森季度调整后的每股收益超出预期，报告为每股 11.69 美元，而预期为 11.56 美元，并指出肿瘤学、专业分销和生物制药服务的强劲表现。路透社文章</li>
<li>积极情绪：该公司预计 2027 财年的每股收益为 43.80-44.60 美元，基本符合预期，并暗示持续的盈利增长。麦克森还重申了其长期财务目标。雅虎财经文章</li>
<li>积极情绪：摩根大通将其目标价下调至 1,015 美元，低于 1,107 美元，但维持增持评级，暗示当前股价有显著上行空间。Benzinga 文章</li>
<li>积极情绪：William Blair 重申了买入评级，表示麦克森的持久盈利能力和 2027 财年的增长前景超过了短期收入疲软的影响。TipRanks 文章</li>
<li>中性情绪：麦克森推进其 130 亿美元的医疗外科分拆/分离计划，这一战略举措可能随着时间的推移释放价值，但也增加了执行风险。MSN 文章</li>
<li>消极情绪：收入低于华尔街预期，达到 963 亿美元，而预期为 1,013.5 亿美元，进一步加剧了对销售动能减弱的担忧，尽管利润率有所改善。雅虎财经文章</li>
<li>消极情绪：尽管盈利强劲且前景乐观，但由于投资者关注收入短缺和医疗外科业务的短期疲软，该股票一直在下跌。Zacks 文章</li>
</ul>
<h2>内部活动</h2>
<p>在其他新闻中，董事玛丽亚·马丁内斯于 2 月 19 日星期四出售了 349 股该股票。股票以平均价格 939.87 美元出售，总交易额为 328,014.63 美元。出售后，该董事直接持有 301 股公司股票，价值 282,900.87 美元。这代表了他们持股的 53.69% 的减少。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，执行副总裁米歇尔·刘于 3 月 2 日星期一出售了 2,725 股公司的股票。股票以平均价格 990.00 美元出售，总价值为 2,697,750.00 美元。交易后，该执行副总裁直接持有 3,247 股公司股票，价值 3,214,530 美元。此交易代表了他们持股的 45.63% 的减少。有关此销售的更多详细信息可在官方 SEC 披露中找到。在过去的九十天里，内部人士出售了价值 3,205,315 美元的 3,264 股公司股票。公司内部人士持有 0.08% 的股票。</p>
<h2>对麦克森的对冲基金看法</h2>
<ul>
<li>超越收益：5 只超越市场并提高分红的股票</li>
</ul>
<p>几家大型投资者最近对其在 MCK 的持仓进行了调整。奥斯陆养老金保险公司在第一季度购买了麦克森的新股份，价值约 365,000 美元。Glenview Trust Co 在第一季度将其在麦克森的持股增加了 15.4%。Glenview Trust Co 现在拥有 3,274 股公司股票，价值 2,833,000 美元，此前在上个季度又购买了 437 股。Cassaday &amp; Co Wealth Management LLC 在第一季度购买了麦克森的新股份，价值约 64,000 美元。Meeder Asset Management Inc. 在第一季度将其在麦克森的持股增加了 20,237.5%。Meeder Asset Management Inc. 现在拥有 8,135 股公司股票，价值 7,040,000 美元，此前在上个季度又购买了 8,095 股。最后，Dimensional Fund Advisors LP 在第一季度将其在麦克森的持股增加了 1.2%。Dimensional Fund Advisors LP 现在拥有 356,397 股公司股票，价值 308,388,000 美元，此前在上个季度又购买了 4,311 股。机构投资者和对冲基金持有公司 85.07% 的股票。</p>
<h2>麦克森股票表现</h2>
<p>周一，NYSE MCK 的股票开盘价为 734.93 美元。该股票的市值为 900.2 亿美元，市盈率为 19.10，市盈增长比率为 1.06，贝塔值为 0.35。该公司的 50 日移动平均线为 883.74 美元，200 日移动平均线为 859.93 美元。麦克森的 52 周低点为 637.00 美元，52 周高点为 999.00 美元。</p>
<p>麦克森（NYSE:MCK - 获取免费报告）最近在 5 月 7 日（星期四）发布了季度财报。该公司报告本季度每股收益（EPS）为 11.69 美元，超出分析师一致预期的 11.56 美元，超出幅度为 0.13 美元。该季度公司收入为 963 亿美元，而分析师预期为 1013.5 亿美元。麦克森的股本回报率为负的 345.35%，净利润率为 1.18%。该公司的收入同比增长 6.0%。去年同期，该公司每股收益为 10.12 美元。麦克森已将 2027 财年的指导目标设定为每股收益 43.800-44.600 美元。分析师预测麦克森今年的每股收益将达到 44.25 美元。</p>
<h2>麦克森分红公告</h2>
<p>该公司最近还宣布了一项季度分红，将于 7 月 1 日（星期三）支付。6 月 1 日（星期一）登记在册的股东将获得 0.82 美元的分红。除息日为 6 月 1 日（星期一）。这相当于年化分红为 3.28 美元，分红收益率为 0.4%。麦克森的分红支付比率（DPR）为 8.53%。</p>
<h2>麦克森公司简介</h2>
<p>（获取免费报告）</p>
<p>麦克森公司（NYSE: MCK）是一家全球医疗保健服务和分销公司，提供药品、医疗外科产品和医疗技术解决方案。公司成立于 1833 年，总部位于德克萨斯州欧文，麦克森在药品分销和医疗服务价值链中运营，连接制造商、药店、医院和医疗系统，以帮助管理药品和临床供应的流动。</p>
<p>公司的核心业务包括药品批发分销和物流、专业药房服务，以及向急性和非急性护理提供者提供医疗外科用品。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过麦克森</li>
<li>超越 NVIDIA：强劲势头的人工智能相关股票</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后看到提振，FanDuel 显示复苏迹象</li>
<li>三只医疗保健股票将从一项重大法案中受益</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1DSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1DSw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在麦克森吗？</h2>
<p>在考虑麦克森之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而麦克森并不在名单上。</p>
<p>虽然麦克森目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

麦克森

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>麦克森公司（NYSE:MCK）获得了十七家券商的 “适度买入” 平均评级。三位分析师给予其持有评级，而十四位分析师推荐买入。平均 12 个月目标价为 970.73 美元。最近的报告显示情绪不一：摩根大通将目标价下调至 1,015 美元，但维持了超配评级，而收入为 963 亿美元，未能达到预期。内部人士的卖出活动被注意到，执行官们出售了大量股份。对冲基金也调整了在麦克森的持仓，一些基金增加了其股份</p>

<p>McKesson Corporation (NYSE:MCK - Get Free Report) has been given an average recommendation of &#34;Moderate Buy&#34; by the seventeen brokerages that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $970.7333.</p>
<div class="lb-trans"><p>麦克森公司（NYSE:MCK - 获取免费报告）获得了覆盖该公司的十七家券商的平均推荐评级为 “适度买入”，Marketbeat 报道。三位投资分析师对该股票给予了持有评级，十四位分析师给予了买入评级。在过去一年中更新了对该股票覆盖的券商中，平均 12 个月目标价为 970.7333 美元。</p>
</div><ul>
<li>3 Stocks That Could Be Next to Announce a Stock Split</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只可能下一个宣布股票拆分的股票</li>
</ul>
</div><p>A number of research firms have recently issued reports on MCK. JPMorgan Chase &amp; Co. cut their target price on shares of McKesson from $1,107.00 to $1,015.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday. Leerink Partners reiterated an &#34;outperform&#34; rating and issued a $1,085.00 target price on shares of McKesson in a research note on Thursday, March 5th. Evercore reiterated an &#34;outperform&#34; rating on shares of McKesson in a research note on Thursday, March 5th. Raymond James Financial set a $970.00 target price on shares of McKesson in a research note on Thursday, March 5th. Finally, Deutsche Bank Aktiengesellschaft restated a &#34;buy&#34; rating and issued a $875.00 target price on shares of McKesson in a research note on Friday.</p>
<div class="lb-trans"><p>一些研究公司最近对 MCK 发布了报告。摩根大通将麦克森的目标价从 1,107.00 美元下调至 1,015.00 美元，并在周五的研究报告中对该公司给予了 “增持” 评级。Leerink Partners 在 3 月 5 日的研究报告中重申了 “跑赢大盘” 评级，并对麦克森的股票设定了 1,085.00 美元的目标价。Evercore 在 3 月 5 日的研究报告中重申了对麦克森股票的 “跑赢大盘” 评级。Raymond James Financial 在 3 月 5 日的研究报告中设定了麦克森股票的 970.00 美元目标价。最后，德意志银行在周五的研究报告中重申了 “买入” 评级，并对麦克森股票设定了 875.00 美元的目标价。</p>
</div><p><strong>Read Our Latest Research Report on MCK</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 MCK 的最新研究报告</strong></p>
</div><h2>Trending Headlines about McKesson</h2>
<div class="lb-trans"><h2>关于麦克森的热门头条</h2>
</div><ul>
<li>3 Dividend Growth Stocks Quietly Raising Payouts</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只悄然提高分红的股息增长股票</li>
</ul>
</div><p>Here are the key news stories impacting McKesson this week:</p>
<div class="lb-trans"><p>以下是本周影响麦克森的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: McKesson beat quarterly adjusted EPS estimates, reporting $11.69 per share versus $11.56 expected, and cited strength in oncology, specialty distribution, and biopharma services. Reuters article</li>
<li>Positive Sentiment: The company guided fiscal 2027 EPS to $43.80-$44.60, which is roughly in line with expectations and suggests continued earnings growth. McKesson also reaffirmed its long-term financial targets. Yahoo Finance article</li>
<li>Positive Sentiment: JPMorgan lowered its price target to $1,015 from $1,107 but kept an overweight rating, implying meaningful upside from the current share price. Benzinga article</li>
<li>Positive Sentiment: William Blair reiterated a Buy rating, saying McKesson’s durable earnings power and fiscal 2027 growth outlook outweigh near-term revenue softness. TipRanks article</li>
<li>Neutral Sentiment: McKesson advanced plans for its $13 billion medical-surgical spinoff/separation, a strategic move that could unlock value over time but also adds execution risk. MSN article</li>
<li>Negative Sentiment: Revenue came in below Wall Street forecasts at $96.3 billion versus $101.35 billion expected, reinforcing concerns about softer sales momentum despite improved margins. Yahoo Finance article</li>
<li>Negative Sentiment: The stock has been trading lower as investors focus on the revenue shortfall and near-term softness in the medical-surgical business, even with strong earnings and guidance. Zacks article</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：麦克森季度调整后的每股收益超出预期，报告为每股 11.69 美元，而预期为 11.56 美元，并指出肿瘤学、专业分销和生物制药服务的强劲表现。路透社文章</li>
<li>积极情绪：该公司预计 2027 财年的每股收益为 43.80-44.60 美元，基本符合预期，并暗示持续的盈利增长。麦克森还重申了其长期财务目标。雅虎财经文章</li>
<li>积极情绪：摩根大通将其目标价下调至 1,015 美元，低于 1,107 美元，但维持增持评级，暗示当前股价有显著上行空间。Benzinga 文章</li>
<li>积极情绪：William Blair 重申了买入评级，表示麦克森的持久盈利能力和 2027 财年的增长前景超过了短期收入疲软的影响。TipRanks 文章</li>
<li>中性情绪：麦克森推进其 130 亿美元的医疗外科分拆/分离计划，这一战略举措可能随着时间的推移释放价值，但也增加了执行风险。MSN 文章</li>
<li>消极情绪：收入低于华尔街预期，达到 963 亿美元，而预期为 1,013.5 亿美元，进一步加剧了对销售动能减弱的担忧，尽管利润率有所改善。雅虎财经文章</li>
<li>消极情绪：尽管盈利强劲且前景乐观，但由于投资者关注收入短缺和医疗外科业务的短期疲软，该股票一直在下跌。Zacks 文章</li>
</ul>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, Director Maria Martinez sold 349 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total transaction of $328,014.63. Following the sale, the director directly owned 301 shares of the company's stock, valued at $282,900.87. This represents a 53.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, EVP Michele Lau sold 2,725 shares of the company's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total value of $2,697,750.00. Following the transaction, the executive vice president directly owned 3,247 shares in the company, valued at $3,214,530. This trade represents a 45.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 3,264 shares of company stock worth $3,205,315. 0.08% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事玛丽亚·马丁内斯于 2 月 19 日星期四出售了 349 股该股票。股票以平均价格 939.87 美元出售，总交易额为 328,014.63 美元。出售后，该董事直接持有 301 股公司股票，价值 282,900.87 美元。这代表了他们持股的 53.69% 的减少。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，执行副总裁米歇尔·刘于 3 月 2 日星期一出售了 2,725 股公司的股票。股票以平均价格 990.00 美元出售，总价值为 2,697,750.00 美元。交易后，该执行副总裁直接持有 3,247 股公司股票，价值 3,214,530 美元。此交易代表了他们持股的 45.63% 的减少。有关此销售的更多详细信息可在官方 SEC 披露中找到。在过去的九十天里，内部人士出售了价值 3,205,315 美元的 3,264 股公司股票。公司内部人士持有 0.08% 的股票。</p>
</div><h2>Hedge Funds Weigh In On McKesson</h2>
<div class="lb-trans"><h2>对麦克森的对冲基金看法</h2>
</div><ul>
<li>More Than Yield: 5 Stocks Beating the Market and Hiking Dividends</li>
</ul>
<div class="lb-trans"><ul>
<li>超越收益：5 只超越市场并提高分红的股票</li>
</ul>
</div><p>Several large investors have recently made changes to their positions in MCK. Oslo Pensjonsforsikring AS bought a new stake in shares of McKesson during the first quarter worth approximately $365,000. Glenview Trust Co raised its stake in shares of McKesson by 15.4% during the first quarter. Glenview Trust Co now owns 3,274 shares of the company's stock worth $2,833,000 after buying an additional 437 shares during the last quarter. Cassaday &amp; Co Wealth Management LLC bought a new stake in shares of McKesson during the first quarter worth approximately $64,000. Meeder Asset Management Inc. raised its stake in shares of McKesson by 20,237.5% during the first quarter. Meeder Asset Management Inc. now owns 8,135 shares of the company's stock worth $7,040,000 after buying an additional 8,095 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of McKesson by 1.2% during the first quarter. Dimensional Fund Advisors LP now owns 356,397 shares of the company's stock worth $308,388,000 after buying an additional 4,311 shares during the last quarter. Institutional investors and hedge funds own 85.07% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近对其在 MCK 的持仓进行了调整。奥斯陆养老金保险公司在第一季度购买了麦克森的新股份，价值约 365,000 美元。Glenview Trust Co 在第一季度将其在麦克森的持股增加了 15.4%。Glenview Trust Co 现在拥有 3,274 股公司股票，价值 2,833,000 美元，此前在上个季度又购买了 437 股。Cassaday &amp; Co Wealth Management LLC 在第一季度购买了麦克森的新股份，价值约 64,000 美元。Meeder Asset Management Inc. 在第一季度将其在麦克森的持股增加了 20,237.5%。Meeder Asset Management Inc. 现在拥有 8,135 股公司股票，价值 7,040,000 美元，此前在上个季度又购买了 8,095 股。最后，Dimensional Fund Advisors LP 在第一季度将其在麦克森的持股增加了 1.2%。Dimensional Fund Advisors LP 现在拥有 356,397 股公司股票，价值 308,388,000 美元，此前在上个季度又购买了 4,311 股。机构投资者和对冲基金持有公司 85.07% 的股票。</p>
</div><h2>McKesson Stock Performance</h2>
<div class="lb-trans"><h2>麦克森股票表现</h2>
</div><p>Shares of NYSE MCK opened at $734.93 on Monday. The stock has a market cap of $90.02 billion, a PE ratio of 19.10, a PEG ratio of 1.06 and a beta of 0.35. The business has a fifty day moving average of $883.74 and a two-hundred day moving average of $859.93. McKesson has a 52-week low of $637.00 and a 52-week high of $999.00.</p>
<div class="lb-trans"><p>周一，NYSE MCK 的股票开盘价为 734.93 美元。该股票的市值为 900.2 亿美元，市盈率为 19.10，市盈增长比率为 1.06，贝塔值为 0.35。该公司的 50 日移动平均线为 883.74 美元，200 日移动平均线为 859.93 美元。麦克森的 52 周低点为 637.00 美元，52 周高点为 999.00 美元。</p>
</div><p>McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $11.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $11.56 by $0.13. The company had revenue of $96.30 billion during the quarter, compared to analysts' expectations of $101.35 billion. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The business's revenue was up 6.0% on a year-over-year basis. During the same period last year, the business earned $10.12 earnings per share. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Analysts predict that McKesson will post 44.25 earnings per share for the current year.</p>
<div class="lb-trans"><p>麦克森（NYSE:MCK - 获取免费报告）最近在 5 月 7 日（星期四）发布了季度财报。该公司报告本季度每股收益（EPS）为 11.69 美元，超出分析师一致预期的 11.56 美元，超出幅度为 0.13 美元。该季度公司收入为 963 亿美元，而分析师预期为 1013.5 亿美元。麦克森的股本回报率为负的 345.35%，净利润率为 1.18%。该公司的收入同比增长 6.0%。去年同期，该公司每股收益为 10.12 美元。麦克森已将 2027 财年的指导目标设定为每股收益 43.800-44.600 美元。分析师预测麦克森今年的每股收益将达到 44.25 美元。</p>
</div><h2>McKesson Dividend Announcement</h2>
<div class="lb-trans"><h2>麦克森分红公告</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be paid a $0.82 dividend. The ex-dividend date is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson's dividend payout ratio (DPR) is 8.53%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 7 月 1 日（星期三）支付。6 月 1 日（星期一）登记在册的股东将获得 0.82 美元的分红。除息日为 6 月 1 日（星期一）。这相当于年化分红为 3.28 美元，分红收益率为 0.4%。麦克森的分红支付比率（DPR）为 8.53%。</p>
</div><h2>McKesson Company Profile</h2>
<div class="lb-trans"><h2>麦克森公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.</p>
<div class="lb-trans"><p>麦克森公司（NYSE: MCK）是一家全球医疗保健服务和分销公司，提供药品、医疗外科产品和医疗技术解决方案。公司成立于 1833 年，总部位于德克萨斯州欧文，麦克森在药品分销和医疗服务价值链中运营，连接制造商、药店、医院和医疗系统，以帮助管理药品和临床供应的流动。</p>
</div><p>The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.</p>
<div class="lb-trans"><p>公司的核心业务包括药品批发分销和物流、专业药房服务，以及向急性和非急性护理提供者提供医疗外科用品。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than McKesson</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过麦克森</li>
<li>超越 NVIDIA：强劲势头的人工智能相关股票</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后看到提振，FanDuel 显示复苏迹象</li>
<li>三只医疗保健股票将从一项重大法案中受益</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1DSw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=MCK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in McKesson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在麦克森吗？</h2>
</div><p>Before you consider McKesson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑麦克森之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而麦克森并不在名单上。</p>
</div><p>While McKesson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然麦克森目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

麦克森公司（NYSE:MCK）被券商给予 “适度买入” 的平均评级